As part of its ongoing fungal meningitis investigation, the FDA draws attention to Ameridose, a second Massachusetts supplier of injectable products.
The US Food and Drug Administration has announced a recall of all products distributed by Ameridose of Massachusetts, a "company sharing common management by the same parties" as the firm implicated in the current fungal meningitis outbreak, due to sterility concerns. The Agency is not suggesting at present that physicians and hospitals locate and contact patients already treated with Ameridose products, merely that they return all unused products received from Ameridose.
The current recall is not connected with any cases of infection from Ameridose products, but arises out of what the Agency calls "an abundance of caution." A list of products available online at ameridose.com includes numerous painkillers such as oxycontin and hydromorphone.
Also, according to a report in the news site MedPage Today, the FDA has found "significant issues" at another Massachusetts firm that prepares sterile injectable medications, Infusion Resource.
To contact Ameridose about return of products, phone 888-820-0622. For the latest information from the FDA, and to speak to a pharmacist at the Agency, phone FDA’s Drug Information Line at 855-543-DRUG (3784) and press * (star).